eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
2/2020
vol. 24
 
Share:
Send email
Share:
abstract:
Original paper

Real-world treatment practice in patients with advanced melanoma

Bożena Cybulska-Stopa
1
,
Karolina Piejko
1
,
Renata Pacholczak
1
,
Małgorzata Domagała-Haduch
1
,
Anna Drosik-Kwaśniewska
1
,
Janusz Rolski
1
,
Patrycja Wiktor-Mucha
1
,
Tomasz Zemełka
1

  1. Clinical Oncology Department, Maria Sklodowska-Curie National Research Institute of Oncology Krakow Branch, Krakow, Poland
Contemp Oncol (Pozn) 2020; 24 (2): 118-124
DOI: https://doi.org/10.5114/wo.2020.97607
Online publish date: 2020/07/03
View full text Get citation
 
PlumX metrics:
Introduction
The treatment outcomes of patients with advanced/metastatic melanoma were poor before the use of new therapeutic options.

Material and methods
A retrospective analysis was conducted among 287 patients with unresectable stage III and stage IV melanoma treated at the Maria Sklodowska-Curie National Research Institute of Oncology Cracow Branch, from 2013 to 2019. All enrolled patients were treated with immunotherapy (IT; consisting of pembrolizumab/nivolumab, or ipilimumab) or target therapy (TT; consisting of vemurafenib ±cobimetinib or dabrafenib ±trametinib) in at least one treatment line.

Results
mutation was detected in 152 (55%) patients. In general, the majority of patients (92%) were in very good or good condition (Eastern Cooperative Oncology Group [ECOG] 0 or 1). Brain metastasis was detected in 64 (22%) patients. Median OS and PFS in the experimental group from the beginning of the first-line treatment were 14.9 and 6.7 months, respectively. Across the study population, as a first-line treatment patients received IT, TT as well as CHT, and the median OS was 19.2, 12.6 and 15.9 months, respectively. Multivariate analysis confirmed that normal LDH levels, no brain metastases, ECOG 0, and objective response to the treatment were strong predictors of longer OS. For PFS, absence of brain metastases, ECOG 0, and treatment response were found to be predictive factors on multivariate analysis.

Conclusions
The administration of new therapies for the treatment of patients with advanced/disseminated melanoma significantly prolonged survival in this group of patients. Nevertheless, further studies should be conducted to assess the effectiveness of various sequences of treatment.

keywords:

melanoma, metastases, immunotherapy, targeted therapy, prognostic factors, real-world data
FEATURED PRODUCTS
BOOKS
• Genetyka i leczenie chłoniaka rozlanego z dużych komórek B (DLBCL)
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.